ABBVIE INC. Last 5 Year Stock GraphThe above graph shows the monthly share price for Abbvie Inc. over the graph period. The share price tells us how much it would cost to buy one share in the company and the graph highlights recent trends. The company is referred to as Abbvie Inc., and the business was formed in 2012. The official description of the company is as follows AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses. The company is among the top players in the global market, with a market capitalization to match. The market capitalisation is 259603112760. This metric is derived by multiplying the number of available shares by the current share price, representing the company’s market value. Abbvie Inc. – Financial OverviewThe company is currently trading at -14.3% below its 52-week high. The 52 week high provides interested parties with the idea of how much the security has moved in the last year and whether it is trading near this high. The price to earnings ratio of the company is 30.2584, this number indicates the amount a company earns compared to the price it costs to buy the company. Some investors would see a low price to earnings ratio provides as providing value. Analysts will usually compare price to earnings ratio of companies within the same industry group. Companies with high price to earnings ratio are considered as growth stocks, whilst companies with low price to earnings ratio are considered as value stocks. The beta of Abbvie Inc. is 0.5424, this is a technical term for the level of volatility a company has when compared to the overall market. The S&P 500 has a beta of 1, so stocks with beta values greater than 1 tend to move with more momentum when compared to the overall stock market and is therefore more volatile than the overall stock market. Whilst betas of less than 1 signal that the stock is less volatile than the market and may be safer, in times of uncertainty, certain investors will increase the number of stocks that have betas less than one. Abbvie Inc. – Investment ProfitsIf you would have invested $100 in ABBVIE INC. 5 years ago today, you would have made a profit of $51.01. Abbvie Inc. – Key Metrics Updated DailyOfficial Name Abbvie Inc. Beta: 0.5424 52 Week High: 168.11 52 Week Low: 130.9601 Change: -1.16 Number of Employees: 50000 Exchange: New York Stock Exchange Headquarters: 1 N Waukegan Rd, NORTH CHICAGO, IL, 60064 US Industry: Pharmaceuticals Year incorporated: 2012
Abbvie Inc. – What to look out for in 2023Here are 10 key bullet points investors should look out for when investing in AbbVie:
|
